抗HER2靶向治疗乳腺癌患者对预后的影响

Effect of Anti HER2 Targeted Treatment on the Prognosis of Breast Cancer Patients

目的:探讨乳腺癌抗人表皮生长因子受体–2(HER2)靶向治疗对患者预后的影响。方法:回顾性选取2021年1月至2022年2月江西省妇幼保健院乳腺科收治的乳腺癌患者80例,依据治疗方法的不同分为常规方案化疗组、抗HER2靶向治疗组(常规方案化疗+抗HER2靶向治疗),每组各40例。比较两组患者临床疗效、疼痛程度、手部功能、上肢功能、负面情绪情况、生活质量、肩关节活动度、不良反应发生率。结果:抗HER2靶向治疗组患者客观缓解率高于常规方案化疗组,差异具有统计学意义(P<0.05)。用药后,抗HER2靶向治疗组患者视觉模拟评分法(VAS)、上肢功能评定量表(DASH)、医院焦虑抑郁量表(HADS)评分低于常规方案化疗组,乳腺癌生命质量测定量表、简易上肢功能评定量表(STEF)评分以及肩关节活动度高于常规方案化疗组,差异具有统计学意义(P<0.05)。抗HER2靶向治疗组患者不良反应总发生率低于常规方案化疗组,差异具有统计学意义(P<0.05)。结论:乳腺癌抗HER2靶向治疗能够有效改善患者预后,可提高临床疗效,改善患者生活质量,且安全性高。

Objective To investigate the effect of anti human epidermal growthfactor receptor 2(HER2)targeted treatment on the prognosis of breast cancer patients.Methods Eighty cases of breast cancer patients admitted to the breast department of Jiangxi Maternal and Child Health Hospital from January 2021 to February 2022 were retrospectively selected.According to the different treatment methods,they were divided into conventional chemotherapy group and anti HER2 targeted treatment group(conventional chemotherapy+anti HER2 targeted treatment),with 40 cases in each group.The clinical efficacy,pain level,hand function,upper limb function,negative emotional status,quality of life,shoulder joint mobility,and incidence of adverse reactions between two groups of patients were compared.Results The objective remission rate of patients in the anti HER2 targeted treatment group was higher than that in the conventional chemotherapy group,and the difference was statistically significant(P<0.05).After treatment,the scores of visual analogue scale(VAS),disabilities of the arm,shoulder and hand scale(DASH),hospital anxiety and depression scale(HADS)in the anti HER2 targeted treatment group were lower than those in the conventional chemotherapy group,while the scores of breast cancer quality of life scale,shortened version of the test evaluation functional(STEF)and shoulder joint activity were higher than those in the conventional chemotherapy group,with statistical significance(P<0.05).The total incidence of adverse reactions in the anti HER2 targeted treatment group was lower than that in the conventional chemotherapy group,and the difference was statistically significant(P<0.05).Conclusion Anti HER2 targeted treatment for breast cancer can effectively improve the prognosis of patients,improve the clinical efficacy,improve the quality of life of patients,and has high safety.